Role of transcription factors in midline central nervous system and pituitary defects

Endocrine Development

Volumn 14, Issue , 2009, Pages 67-82

  Kelberman, Daniel ^a   Dattani, Mehul Tulsidas ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; HYPOPHYSIS HORMONE; PAIRED LIKE HOMEODOMAIN TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HESX1; TRANSCRIPTION FACTOR LHX3; TRANSCRIPTION FACTOR LHX4; TRANSCRIPTION FACTOR PIT 1; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR SOX3; UNCLASSIFIED DRUG;

ADENOHYPOPHYSIS; CENTRAL NERVOUS SYSTEM MALFORMATION; CONFERENCE PAPER; EXPERIMENTAL MODEL; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GROWTH HORMONE DEFICIENCY; GROWTH REGULATION; GROWTH RETARDATION; HOMEOSTASIS; HORMONE DEFICIENCY; HORMONE RELEASE; HUMAN; HYPOPHYSIS DISEASE; HYPOPITUITARISM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; REPRODUCTION; SEPTOOPTIC DYSPLASIA; SIGNAL TRANSDUCTION; ANIMAL; CONGENITAL MALFORMATION; GENETICS; HYPOPHYSIS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; HUMANS; HYPOPITUITARISM; PITUITARY GLAND; TRANSCRIPTION FACTORS;

EID: 65549085783     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000207478     Document Type: Conference Paper

References (94)

1. Takuma N, Sheng HZ, FurutaY, Ward JM, Sharma K, Hogan BL, Pfaff SL, Westphal H, Kimura S, Mahon KA: Formation of Rathke's pouch requires dual induction from the diencephalon. Development 1998;125:4835-4840.
2. Dasen JS, Rosenfeld MG: Signaling mechanisms in pituitary morphogenesis and cell fate determination. Curr Opin Cell Biol 1999;11:669-677.
3. Dasen JS, Rosenfeld MG: Signaling and transcriptional mechanisms in pituitary development. Annu Rev Neurosci 2001;24:327-355.
4. Rizzoti K, Lovell-Badge R: Early development of the pituitary gland: induction and shaping of Rathke's pouch. Rev Endocr Metab Disord 2005;6:161-172.
5. de Morsier G: Studies in cranio-encephalic dysraphia. I: Agenesis of the olfactory lobe (lateral telencephaloschisis) and of the callous and anterior commissures (median telencephaloschisis); olfactogenital dysplasia. Schweiz Arch Neurol Psychiatr 1954;74:309-361.
6. Reeves DL: Congenital absence of the septum pellucidum. Bull Johns Hopkins Hosp 1941;69:61-71.
7. Hoyt WF, Kaplan SL, Grumbach MM, Glaser JS: Septo-optic dysplasia and pituitary dwarfism. Lancet 1970;i:893-894.
8. Arslanian SA, Rothfus WE, Foley TP Jr, Becker DJ: Hormonal, metabolic, and neuroradiologic abnormalities associated with septo-optic dysplasia. Acta Endocrinol (Copenh) 1984;107:282-288.
9. Stanhope R, Preece MA, Brook CG: Hypoplastic optic nerves and pituitary dysfunction. A spectrum of anatomical and endocrine abnormalities. Arch Dis Child 1984;59:111-114.
10. Dattani MT, Martinez-Barbera JP et al: Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. Nat Genet 1998;19:125-133.
11. Thomas PQ, Dattani MT, Brickman JM et al: Heterozygous HESX1 mutations associated with isolated congenital pituitary hypoplasia and septooptic dysplasia. Hum Mol Genet 2001;10:39-45.
12. Sobrier ML, Netchine I, Heinrichs C, Thibaud N, Vie-Luton M P, Van VG, Amselem S: Alu-element insertion in the homeodomain of HESX1 and aplasia of the anterior pituitary. Hum Mutat 2005; 25: 503.
13. McNay DE, Turton J P, Kelberman D et al: HESX1 mutations are an uncommon cause of septooptic dysplasia and hypopituitarism. J Clin Endocrinol Metab 2007;92:691-697.
14. Patel L, McNally RJ, Harrison E, Lloyd IC, Clayton PE: Geographical distribution of optic nerve hypoplasia and septo-optic dysplasia in Northwest England. J Pediatr 2006;148:85-88.
15. Tornqvist K, Ericsson A, Kallen B: Optic nerve hypoplasia: Risk factors and epidemiology. Acta Ophthalmol Scand 2002;80:300-304.
16. Laumonnier F, Ronce N, Hamel BCJ et al: Transcription factor SOX3 is involved in X-linked mental retardation with growth hormone deficiency. Am J Hum Genet 2002;71:1450-1455.
17. Stevanovic M, Lovellbadge R, Collignon J, Good-fellow PN: Sox3 is an X-linked gene-related to Sry. Hum Mol Genet 1993;2:2013-2018.
18. Pevny LH, Lovell-Badge R: Sox genes find their feet. Curr Opin Genet Dev 1997;7:338-344.
19. Kamachi Y, Uchikawa M, Collignon J, Lovell-Badge R, Kondoh H: Involvement of Sox1, 2 and 3 in the early and subsequent molecular events of lens induction. Development 1998;125:2521-2532.
20. Pevny L, Placzek M: SOX genes and neural progenitor identity. Curr Opin Neurobiol 2005;15:7-13.
21. Rizzoti K, Brunelli S, Carmignac D, Thomas PQ, Robinson IC, Lovell-Badge R: SOX3 is required during the formation of the hypothalamo-pituitary axis. Nat Genet 2004;36:247-255.
22. Weiss J, Meeks JJ, Hurley L, Raverot G, Frassetto A, Jameson JL: Sox3 is required for gonadal function, but not sex determination, in males and females. Mol Cell Biol 2003;23:8084-8091.
23. Hamel BC, Smits A P, Otten BJ, van den HB, Ropers HH, Mariman EC: Familial X-linked mental retardation and isolated growth hormone deficiency: clinical and molecular findings. Am J Med Genet 1996;64:35-41.
24. Lagerstrom-Fermer M, Sundvall M, Johnsen E, Warne GL, Forrest SM, Zajac JD, Rickards A, Ravine D, Landegren U, Pettersson U: X-linked recessive panhypopituitarism associated with a regional duplication in Xq25-q26. Am J Hum Genet 1997; 60:910-916.
25. Hol FA, Schepens MT, van Beersum SE, Redolfi E, Affer M, Vezzoni P, Hamel BC, Karnes PS, Mariman EC, Zucchi I: Identification and characterization of an Xq26-q27 duplication in a family with spina bifida and panhypopituitarism suggests the involvement of two distinct genes. Genomics 2000;69: 174-181.
26. Solomon NM, Nouri S, Warne GL, Lagerstrom-Fermer M, Forrest SM, Thomas PQ: Increased gene dosage at Xq26-q27 is associated with X-linked hypopituitarism. Genomics 2002;79:553-559.
27. Woods KS, Cundall M, Turton J, Rizotti K, Mehta A, Palmer R, Wong J, Chong WK, Al Zyoud M, El Ali M et al: Over- and underdosage of SOX3 is associated with infundibular hypoplasia and hypopituitarism. Am J Hum Genet 2005;76:833-849.
28. Albrecht AN, Kornak U, Boddrich A, Suring K, Robinson PN, Stiege AC, Lurz R, Stricker S, Wanker EE, Mundlos S: A molecular pathogenesis for transcription factor associated poly-alanine tract expansions. Hum Mol Genet 2004;13:2351-2359.
29. Wood HB, Episkopou V: Comparative expression of the mouse Sox1, Sox2 and Sox3 genes from pregastrulation to early somite stages. Mech Dev 1999; 86:197-201.
30. Williamson KA, Hever AM, et al: Mutations in SOX2 cause anophthalmia-esophageal-genital (AEG) syndrome. Hum Mol Genet 2006;15:1413-1422.
31. Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R: Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev 2003;17:126-140.
32. Taranova O V, Magness ST, Fagan BM, Wu Y, Surzenko N, Hutton SR, Pevny LH: SOX2 is a dose-dependent regulator of retinal neural progenitor competence. Genes Dev 2006;20:1187-1202.
33. Kelberman D, Rizzoti K, Avilion A et al: Mutations withinSox2/SOX2 are associated with abnormalities in the hypothalamo-pituitary-gonadal axis in mice and humans. J Clin Invest 2006;116:2442-2455.
34. Fantes J, Ragge NK, Lynch SA, et al: Mutations in SOX2 cause anophthalmia. Nat Genet 2003;33:461-463.
35. Ragge NK, Lorenz B, Schneider A, et al: SOX2 anophthalmia syndrome. Am J Med Genet 2005; 135A:1-7.
36. Hagstrom SA, Pauer GJT, Reid J, Simpson E, Crowe S, Maumenee IH, Traboulsi EI: SOX2 mutation causes anophthalmia, hearing loss, and brain anomalies. Am J Med Genet 2005;138A:95-98.
37. Zenteno JC, Gascon-Guzman G, Tovilla-Canales JL: Bilateral anophthalmia and brain malformations caused by a 20-bp deletion in the SOX2 gene. Clin Genet 2005;68:564-566.
38. Sato N, Kamachi Y, Kondoh H, Shima Y, Morohashi K, Horikawa R, Ogata T: Hypogonadotropic hypog-onadism in an adult female with a heterozygous hypomorphic mutation of SOX2. Eur J Endocrinol 2007;156:167-171.
39. Chassaing N, Gilbert-Dussardier B, Nicot F, Fermeaux V, Encha-Razavi F, Fiorenza M, Toutain A, Calvas P: Germinal mosaicism and familial recurrence of a SOX2 mutation with highly variable phenotypic expression extending from AEG syndrome to absence of ocular involvement. Am J Med Genet [A] 2007;143:289-291.
40. Bakrania P, Robinson DO, Bunyan DJ et al: SOX2 anophthalmia syndrome: twelve new cases demonstrating broader phenotype and high frequency of large gene deletions. Br J Ophthalmol 2007;91,1471-1476
41. Guichet A, Triau S, Lepinard C, Esculapavit C, Biquard F, Descamps P, Encha-Razavi F, Bonneau D: Prenatal diagnosis of primary anophthalmia with a 3q27 interstitial deletion involving SOX2. Prenat Diagn 2004;24:828-832.
42. Faivre L, Williamson KA, Faber V et al: Recurrence of SOX2 anophthalmia syndrome with gonosomal mosaicism in a phenotypically normal mother. Am J Med Genet [A] 2006;140:636-639.
43. Kelberman D, de Castro SC, Huang S et al: SOX2 plays a critical role in the pituitary, forebrain and eye during human embryonic development. J Clin Endocrinol Metab 2008;in press.
44. Bach I, Rhodes SJ, Pearse RV, Heinzel T, Gloss B, Scully KM, Sawchenko PE, Rosenfeld MG: P-Lim, a LIM homeodomain factor, is expressed during pituitary organ and cell commitment and synergizes with Pit-1. Proc Natl Acad Sci USA 1995;92:2720-2724.
45. Schmitt S, Biason-Lauber A, Betts D, Schoenle EJ: Genomic structure, chromosomal localization, and expression pattern of the human LIM-Homeobox3 (LHX 3) gene. Biochem Biophys Res Commun 2000;274:49-56.
46. Zhadanov AB, Bertuzzi S, Taira M, Dawid IB, Westphal H: Expression pattern of the murine lim class homeobox gene Lhx3 in subsets of neural and neuroendocrine tissues. Dev Dynam 1995;202:354-364.
47. Sheng HZ, Zhadanov AB, Mosinger B, Fujii T, Bertuzzi S, Grinberg A, Lee EJ, Huang SP, Mahon KA, Westphal H: Specification of pituitary cell lineages by the LIM homeobox gene Lhx3. Science 1996;272:1004-1007.
48. Sheng HZ, Moriyama K, Yamashita T, Li H, Potter SS, Mahon KA, Westphal H: Pituitary organogenesis controlled by LIM-homeobox genes. Dev Biol 1997; 186, B132.
49. Netchine I, Sobrier ML, Krude H, et al: Mutations in LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency. Nat Genet 2000;25:182-186.
50. Sloop K W, Parker GE, Hanna KR, Wright HA, Rhodes SJ: LHX3 transcription factor mutations associated with combined pituitary hormone deficiency impair the activation of pituitary target genes. Gene 2001;265:61-69.
51. Bhangoo AP, Hunter CS, Savage JJ, Anhalt H, Pavlakis S, Walvoord EC, Ten S, Rhodes SJ: A novel LHX3 mutation presenting as combined pituitary hormonal deficiency. J Clin Endocrinol Metab 2006; 91:747-753.
52. Sobrier ML, Attie-Bitach T, Netchine I, Encha-Razavi F, Vekemans M, Amselem S: Pathophysiology of syndromic combined pituitary hormone deficiency due to a LHX3 defect in light of LHX3 and LHX4 expression during early human development. Gene Expression Patterns 2004;5:279-284.
53. Pfaeffle RW, Savage JJ, Hunter CS et al: Four novel mutations of the LHX3 gene cause combined pituitary hormone deficiencies with or without limited neck rotation. J Clin Endocrinol Metab 2007; 92:1909-1919.
54. Sheng HZ, Moriyama K, Yamashita T, Li H, Potter SS, Mahon KA, Westphal H: Multistep control of pituitary organogenesis. Science 1997;278:1809-1812.
55. Machinis K, Pantel J, Netchine I et al: Syndromic short stature in patients with a germline mutation in the LIM homeobox LHX4. Am J Hum Genet 2001; 69:961-968.
56. Tajima T, Hattori T, Nakajima T, Okuhara K, Tsubaki J, Fujieda K: A novel missense mutation (P366T) of the LHX4 gene causes severe combined pituitary hormone deficiency with pituitary hypoplasia, ectopic posterior lobe and a poorly developed sella turcica. Endocr J 2007;54:637-641.
57. Sornson M W, Wu W, Dasen JS et al: Pituitary lineage determination by the Prophet of Pit-1 homeo-domain factor defective in Ames dwarfism. Nature 1996;384:327-333.
58. Gage PJ, Roller ML, Saunders TL, Scarlett LM, Camper SA: Anterior pituitary cells defective in the cell-autonomous factor, df, undergo cell lineage specification but not expansion. Development 1996; 122:151-160.
59. Tang K, Bartke A, Gardiner CS, Wagner TE, Yun JS: Gonadotropin secretion, synthesis, and gene expression in human growth hormone transgenic mice and in Ames dwarf mice. Endocrinology 1993;132: 2518-2524.
60. Wu W, Cogan JD, Pfaffle RW et al: Mutations in PROP1 cause familial combined pituitary hormone deficiency. Nat Genet 1998;18:147-149.
61. Deladoey J, Fluck C, Buyukgebiz A, Kuhlmann BV, Eble A, Hindmarsh PC, Wu W, Mullis PE: 'Hot spot' in the PROP1 gene responsible for combined pituitary hormone deficiency. J Clin Endocrinol Metab 1999;84:1645-1650.
62. Cogan JD, Wu W, Phillips JA III, Arnhold IJ, Agapito A, Fofanova O V, Osorio MG, Bircan I, Moreno A, Mendonca BB: The PROP1 2-base pair deletion is a common cause of combined pituitary hormone deficiency. J Clin Endocrinol Metab 1998;83:3346-3349.
63. Turton JPG, Mehta A, Raza J et al: Mutations within the transcription factor PROP1 are rare in a cohort of patients with sporadic combined pituitary hormone deficiency (CPHD). Clin Endocrinol 2005;63: 10-18.
64. Duquesnoy P, Roy A, Dastot F, et al: Human Prop-1:cloning, mapping, genomic structure: mutations in familial combined pituitary hormone deficiency. FEBS Lett 1998;437:216-220.
65. Reynaud R, Chadli-Chaieb M, Vallette-Kasic S, Barlier A, Sarles J, Pellegrini-Bouiller I, Enjalbert A, Chaieb L, Brue T: A familial form of congenital hypopituitarism due to a PROP1 mutation in a large kindred: phenotypic and in vitro functional studies. J Clin Endocrinol Metab 2004;89:5779-5786.
66. Osorio MG, Kopp P, Marui S, Latronico AC, Mendonca BB, Arnhold IJ: Combined pituitary hormone deficiency caused by a novel mutation of a highly conserved residue (F88S) in the homeodo-main of PROP-1. J Clin Endocrinol Metab 2000;85: 2779-2785.
67. Lebl J, Vosahlo J, Pfaeffle RW et al: Auxological and endocrine phenotype in a population-based cohort of patients with PROP1 gene defects. Eur J Endocrinol 2005;153:389-396.
68. Reynaud R, Barlier A, Vallette-Kasic S, Saveanu A, Guillet M P, Simonin G, Enjalbert A, Valensi P, Brue T: An uncommon phenotype with familial central hypogonadism caused by a novel PROP1 gene mutant truncated in the transactivation domain. J Clin Endocrinol Metab 2005;90:4880-4887.
69. Arroyo A, Pernasetti F, Vasilyev VV, Amato P, Yen SS, Mellon PL: A unique case of combined pituitary hormone deficiency caused by a PROP1 gene mutation (R120C) associated with normal height and absent puberty. Clin Endocrinol (Oxf) 2002;57:283-291.
70. Fluck C, Deladoey J, Rutishauser K, Eble A, Marti U, Wu W, Mullis PE: Phenotypic variability in familial combined pituitary hormone deficiency caused by a PROP1 gene mutation resulting in the substitution of Arg->Cys at codon 120 (R120C). J Clin Endocrinol Metab 1998;83:3727-3734.
71. Vallette-Kasic S, Barlier A, Teinturier C et al: PROP1 gene screening in patients with multiple pituitary hormone deficiency reveals two sites of hypermutability and a high incidence of corticotroph deficiency. J Clin Endocrinol Metab 2001;86: 4529-4535.
72. Mendonca BB, Osorio MG, Latronico AC, Estefan V, Lo LS, Arnhold IJ: Longitudinal hormonal and pituitary imaging changes in two females with combined pituitary hormone deficiency due to deletion of A301,G302 in the PROP1 gene. J Clin Endocrinol Metab 1999;84:942-945.
73. Asteria C, Oliveira JH, Abucham J, Beck-Peccoz P: Central hypocortisolism as part of combined pituitary hormone deficiency due to mutations of PROP-1 gene. Eur J Endocrinol 2000;143:347-352.
74. Pernasetti F, Toledo S P, Vasilyev V V, Hayashida CY, Cogan JD, Ferrari C, Lourenco DM, Mellon PL: Impaired adrenocorticotropin-adrenal axis in combined pituitary hormone deficiency caused by a two-base pair deletion (301-302delAG) in the prophet of Pit-1 gene. J Clin Endocrinol Metab 2000;85:390-397.
75. Riepe FG, Partsch CJ, Blankenstein O, Monig H, Pfaffle RW, Sippell WG: Longitudinal imaging reveals pituitary enlargement preceding hypoplasia in two brothers with combined pituitary hormone deficiency attributable to PROP1 mutation. J Clin Endocrinol Metab 2001;86:4353-4357.
76. Bottner A, Keller E, Kratzsch J, Stobbe H, Weigel JF, Keller A, Hirsch W, Kiess W, Blum WF, Pfaffle RW: PROP1 mutations cause progressive deterioration of anterior pituitary function including adrenal insufficiency: a longitudinal analysis. J Clin Endocrinol Metab 2004;89:5256-5265.
77. Agarwal G, Bhatia V, Cook S, Thomas PQ: Adrenocorticotropin deficiency in combined pituitary hormone deficiency patients homozygous for a novel PROP1 deletion. J Clin Endocrinol Metab 2000;85:4556-4561.
78. Fofanova O, Takamura N, Kinoshita E, Vorontsov A, Vladimirova V, Dedov I, Peterkova V, Yamashita S: MR imaging of the pituitary gland in children and young adults with congenital combined pituitary hormone deficiency associated with PROP1 mutations. AJR Am J Roentgenol 2000;174:555-559.
79. Voutetakis A, Argyropoulou M, Sertedaki A, Livadas S, Xekouki P, Maniati-Christidi M, Bossis I, Thalassinos N, Patronas N, Dacou-Voutetakis C: Pituitary magnetic resonance imaging in 15 patients with Prop1 gene mutations: pituitary enlargement may originate from the intermediate lobe. J Clin Endocrinol Metab 2004;89:2200-2206.
80. Parks JS, Brown MR, Baumbach L, et al: Natural history and molecular mechanisms of hypopituitar-ism with large sella turcica. Am Endocrine Soc Meet, New Orleans, 1998, abstr P3-409, p 470.
81. Bodner M, Castrillo JL, Theill LE, Deerinck T, Ellisman M, Karin M: The pituitary-specific transcription factor GHF-1 is a homeobox-containing protein. Cell 1988;55:505-518.
82. Andersen B, Rosenfeld MG: POU domain factors in the neuroendocrine system: lessons from developmental biology provide insights into human disease. Endocr Rev 2001;22:2-35.
83. Rhodes SJ, DiMattia GE, Rosenfeld MG: Trans-criptional mechanisms in anterior pituitary cell differentiation. Curr Opin Genet Dev 1994;4:709-717.
84. Li S, Crenshaw EB III, Rawson EJ, Simmons DM, Swanson LW, Rosenfeld MG: Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene pit-1. Nature 1990; 347:528-533.
85. Andersen B, Rosenfeld MG: Pit-1 determines cell types during development of the anterior pituitary gland: a model for transcriptional regulation of cell phenotypes in mammalian organogenesis. J Biol Chem 1994;269:29335-29338.
86. Rhodes SJ, Chen R, DiMattia GE, Scully KM, Kalla KA, Lin SC, Yu VC, Rosenfeld MG: A tissue-specific enhancer confers Pit-1-dependent morphogen inducibility and autoregulation on the pit-1 gene. Genes Dev 1993;7:913-932.
87. Tatsumi K, Miyai K, Notomi T, Kaibe K, Amino N, Mizuno Y, Kohno H: Cretinism with combined hormone deficiency caused by a mutation in the PIT1 gene. Nat Genet 1992;1:56-58.
88. Cohen LE, Wondisford FE, Salvatoni A, Maghnie M, Brucker-Davis F, Weintraub BD, Radovick S: A 'hot spot' in the Pit-1 gene responsible for combined pituitary hormone deficiency: clinical and molecular correlates. J Clin Endocrinol Metab 1995;80:679-684.
89. Radovick S, Nations M, Du Y, Berg LA, Weintraub BD, Wondisford FE: A mutation in the POU-homeodomain of Pit-1 responsible for combined pituitary hormone deficiency. Science 1992;257:1115-1118.
90. Kishimoto M, Okimura Y, Fumoto M, Iguchi G, Iida K, Kaji H, Chihara K: The R271W mutant form of Pit-1 does not act as a dominant inhibitor of Pit-1 action to activate the promoters of GH and prolactin genes. Eur J Endocrinol 2003;148:619-625.
91. Pfaffle RW, DiMattia GE, Parks JS, Brown MR, Wit JM, Jansen M, Van-der-Nat H, Van-den-Brande JL, Rosenfeld MG, Ingraham HA: Mutation of the POU-specific domain of Pit-1 and hypopituitarism without pituitary hypoplasia. Science 1992;257:1118-1121.
92. Pfaffle RW, Martinez R, Kim C, Frisch H, Lebl J, Otten B, Heimann,G: GH and TSH deficiency. Exp Clin Endocrinol Diabetes 1997;105(suppl 4):1-5.
93. Turton JPG, Reynaud R, Mehta A et al: Novel mutations within the POU1F1 gene associated with variable combined pituitary hormone deficiency. J Clin Endocrinol Metab 2005;90:4762-4770.
94. Cohen LE, Radovick S: Molecular basis of combined pituitary hormone deficiencies. Endocr Rev 2002; 23:431-442.